Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

San Diego, USA
4215 Sorrento Valley Blvd.
San Diego, CA, 92121
USA

People

CFO
President & CEO
President & CEO
Board Director
Board Director
Board Director
Board Director
Board Director
Show All People

Funding

Tags

Ambit Biosciences

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit’s lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit’s clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Recent Milestones

Videos

Screenshots

Sources

  1. SEC (sec.gov) [edit]
  2. SEC (sec.gov) [edit]
  3. SEC (sec.gov) [edit]
  4. AMBIT BIOSCIENCES COMPLETES $30 MILLION SERIES D-2 FINANCING (phx.corporate-ir.net) [edit]
  5. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia (phx.corporate-ir.net) [edit]
Edit This Page
Last Edited 4/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy